A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 734
- Population
- ALL · 50 Years
- Duration
- 2019-09-25 to 2022-09-09
- Intervention
- Brolucizumab 6 mg; Aflibercept 2 mg
- Comparator
- Aflibercept 2 mg
- Outcomes measured
- Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye — Up to Week 32; Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…; Distribution of the Last Interval With no Disease Activity up to Week 64 - Study Eye — Up to Week 64; Distribution of the Maximal Intervals With no Disease Activity up to Week 64 - Study Eye — Up to Week 64; Number of Participants With no Disease Activity - Study Eye — Weeks 14 and 16; Time From Last Loading Injection to First Visit With No Disease Activity (Weeks) - 75th Percentile - Study Eye — Up to…; Time-to-first Dry Retina - Time to the First Visit With no Intraretinal Fluid (IRF) or Subretinal Fluid (SRF) - Study E…; Average Change From Baseline at Week 60 and Week 64 in Best-corrected Visual Acuity (BCVA) - Study Eye — Baseline, Week…; Number of Participants With Best-corrected Visual Acuity Improvements of ≥ 15 Letters in BCVA From Baseline or Reached…; Number of Participants With Best-corrected Visual Acuity ≥ 69 Letters - Study Eye — Week 32 and Week 64; Average Change From Baseline in Central Subfield Thickness (CSFT) - Study Eye — Baseline, Weeks 28 and 32 and at Weeks…; Number of Participants With Presence of Intraretinal Fluid and/or Subretinal Fluid in the Central Subfield - Study Eye…; Number of Participants With Presence of Sub-Retinal Pigment Epithelium Fluid in the Central Subfield - Study Eye — At W…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Composite Scores - Study Eye — Baseline, Week 32,…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - General Vision - Study Eye — Base…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Ocular Pain - Study Eye — Baselin…; Change From Baseline n Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Near Activities - Study Eye — Base…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Distance Activities - Study Eye —…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Social Functioning - Study Eye —…; Change From Baseline in Visual Function Questionnnaire-25 (VFQ-25) - Subscale Score - Mental Health - Study Eye — Basel…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.